Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT: Gardasil9 in BM-EABE With or Without HIV
NCT06624839Phase 2Recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Mar 2025
- Primary completion
- Jan 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by University of Maryland, Baltimore. Started Mar 2025; status: recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT06624839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06624839.